

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gabriel Nunez et al.

Serial No.:

10/002,974

10/26/01

Group No.: Examiner:

1634

Goldberg

Filed: Entitled:

NOD2 Nucleic Acids and Proteins

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 12, 2003

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

A check for \$180.00 is also enclosed pursuant to 37 C.F.R. § 1.17(p) for filing this Information Disclosure Statement after three months as set forth in 37 C.F.R. § 1.97(c).

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: September 12, 2003

Tanya A. Arenson

Registration No. 47,391

09/16/2003 NELBHCO 00000030 10002574

02 FC:1806

130.00 GP

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105

608/218-6900

UM/UC-06646 September 12, 2003



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nunez et al.

Serial No.:

10/002,974

Group No.:

Filed:

10/26/01

Examiner:

Entitled: NOD2 NUCLEIC ACIDS AND PROTEINS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on September 12, 2003.

y: Dryw

Mary Ellen Waite

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- The following publications were cited in the International Search reports of copending PCT Applications WO 02/44426 and WO 02/36773:
- WO 01/72822;
- WO 99/64576;

UM/UC-06646 September 12, 2003



- WO 99/40102;
- WO 01/90156;
- Ogura et al., "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease," Nature Vol 411:603 [2001];
- Hugot et al., "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease," Nature 411:6837 [2001];
- Inohara et al., "The NOD: A signaling module that regulates apoptosis and host defense against pathogens," Oncogene, 20:6473 [2001];
- Ogura et al., "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappa B," J. Biol. Chem. 276:4812 [2001];
- Database EMBL, Human NOD2 protein mRNA, Database accession number AF178930;
- Database EMBL, June 7, 1999 "Sequencing of human chromosome 16,"
 Database accession no. AC007728;
- Database EMBL May 18, 1999 "Use of BAC end sequences from library RPCI 11 for sequence-ready map building," Database Accession No. AQ534686;
- Hugot et al., "Mapping of a susceptibility locus for Crohn's disease on chromosome 16," Nature 379:821 [1996];
- Miceli-Richard et al., "CARD15 mutations in Blau syndrome," Nature Genetics 29:19 [2001]; and
- Inohara et al., "Nods: A family of cytosolic proteins that regulate the host response to pathogens," Curr. Opin. Microbiol. 5:76 [2002].

The following printed publications are referred to in the body of the specification:

- Aderem and Ulevitch, Nature, 406:785-787 [2000];
- Philpott et al., J. Immunol., 165:903-914 [2000];

UM/UC-06646 September 12, 2003

- Leister and Katagiri, Plant J., 22:345-354 [2000];
- Hugot *et al.*, Nature 379:821 [1996];
- Chou et al., Cell, 94:171 [1998];
- Kobe and Deisenhofer, Curr. Opin. Struct Biol., 5:409-416 [1995];
- Zou et al., J. Bio. Chem. 274: 11549-11556 [1999];
- Schwandner et al., J. Biol. Chem., 274: 17406-17409 [2000];
- Inohara et al., J. Biol. Chem. 274: 14560-14568 [1999];
- Li et al., Cell 91: 479-489 [1997];
- Snivasula et al., Mol. Cell 1: 949-957 [1998];
- Hu et al., J. Bio. Chem. 273: 33489-34494 [1998];
- Inohara et al., J. Biol. Chem. 273: 12296-12300 [1998];
- McCarthy *et al.*, J. Bio. Chem. 273, 16968-16975 [1998];
- Parniske *et al.*, Cell 91: 821-832 [1997];
- Dixon et al., Proc. Natl. Acad. Sci. U. S. A. 97: 8807-8814 [2000];
- Aliprantis *et al.*, Science, 285:736-739 [1999];
- Chow et al., J. Biol. Chem., 274:10689-10692 [2000];
- Bertin et al., J. Biol. Chem., 274:12955-12958;
- McCarthy et al., J. Biol. Chem., 273:16968-16975;
- Thome *et al.*, Curr. Biol., 8:885-888 [1998];
- Inohara et al., J. biol. Chem., 275:27823-27831 [2000];
- Shimada *et al.*, Int. Immunol., 11:1357-1362 [1999];
- Huang et al., PNAS, 94:12829-12832 [1997];
- Medzhitov *et al.*, Mol. Cell, 2:253-258 [1998];
- Hsu *et al.*, Immunity, 4:387-396 [1996];
- Yamaoka *et al.*, Cell 93: 1231-1240 [1998];
- Hu et al., EMBO J. 18: 3586-3595 [1999];
- Karin, J. Biol. Chem. 274: 27339-27342 [1999];



- Hofmann et al., Trends Biochem. Sci. 22: 155-156 [1997];
- MacCorkle et al., Proc. Nat. Acad. Sci. U. S. A. 95: 3655-3660 [1998];
- Yang et al., Nature, 395:284-288 [1998];
- Zou et al., Cell, 90:405-413 [1997];
- Poltorak et al., Science, 282:2085 [1998];
- Takeuchi *et al.*, Immunity, 4:443 [1999];
- Rietschel et al., Curr Top. Microbiol. Immunol., 216:39-81 [1997];

Applicants have become aware of the following printed publications which may be material to the examination of this application:

- Cho et al., Inflammatory Bowl Diseases 3:186 [1997];
- Cho et al., Proc. Natl. Acad. Sci. 95:7502 [1998];
- Brant et al., Gastroenterology 115:1056 [1998];
- Cho et al., Hum. Mol. Gent. 9:1425 [2000];
- Cavanaugh et al., Ann. Hum. Gent. 62:291 [1998];
- Tysk et al., Gut 29:990 [1988].

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: September 12, 2003

Tanya A. Arenson

Reg. No. 47,391

MEDLEN & CARROLL, LLP

101 Howard Street, Suite 350

San Francisco, California 94105

608 218-6900

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office			Attorney Docket No.: UM/UC-06646		Serial No.: 10/002,974				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Applicant: Gabriel Nunez et al.						
(Use Several Sheets If Necessary)					Filing Date: 10/26/01	Filing Date: 10/26/01 Group Art Unit:					
(37 CFR § 1.98(b)) U.S. PATENT DOCUMENTS											
Examiner	Cite	Serial / Patent	Issue Date		ant / Patentee	Class	Subclass	Filing	Date		
Initiats 1	No.	Number		••		TIONS					
77 CC-	FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS Translation										
SEP .1 6 2	109	Document Number	Publication Date	Country	/ Patent Office	Class	Subclass	Yes	No		
<i>P</i>	N. C.	WO 01/72822	4 October 01		PCT				Х		
PANAP	2	WO 99/64576	16 December 99	X	PCT						
	3	WO 99/40102	12 August 99	X	PCT						
	4	WO 01/90156	22 November 01	X	PCT						
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)											
	5	Ogura et al., "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease," Nature Vol 411:603 [2001]									
	6	Hugot et al., "Assoc	ciation of NOD2 leuc	ine-rich repeat varian	ts with susceptibility to Cro	hn's disease," N	Nature 411:6837	[2001]			
	7	Inohara et al., "The NOD: A signaling module that regulates apoptosis and host defense against pathogens," Oncogene, 20:6473 [2001]									
	8	Ogura et al., "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappa B," J. Biol. Chem. 276:4812 [2001]									
	9	Database EMBL, Human NOD2 protein mRNA, Database accession number AF178930									
	10	Database EMBL, June 7, 1999 "Sequencing of human chromosome 16," Database accession no. AC007728									
	11	Database EMBL May 18, 1999 "Use of BAC end sequences from library RPCI-11 for sequence-ready map building," Database Accession No. AQ534686									
,	12	Hugot et al., "Mapping of a susceptibility locus for Crohn's disease on chromosome 16," Nature 379:821 [1996]									
	13	Miceli-Richard et al., "CARD15 mutations in Blau syndrome," Nature Genetics 29:19 [2001]									
	14	Inohara et al., "Nods: A family of cytosolic proteins that regulate the host response to pathogens," Curr. Opin. Microbiol. 5:76 [2002]									
	15	Aderem and Ulevitch, Nature, 406:785-787 [2000]									
	16	Philpott et al., J. Immunol., 165:903-914 [2000]									
	17	Leister and Katagiri, Plant J., 22:345-354 [2000]									
	18	Hugot et al., Nature 379:821 [1996]									
	19		Chou et al., Cell, 94:171 [1998]								
	20	Kobe and Deisenhofer, Curr. Opin. Struct Biol., 5:409-416 [1995]									
	21	Zou et al., J. Bio. Chem. 274: 11549-11556 [1999]									
	22	Schwandner et al., J. Biol. Chem., 274; 17406-17409 [2000]									
	23	Inohara et al., J. Biol. Chem. 274;14560-14568 [1999]									
	24	Li et al., Cell 91: 479-489 [1997]									
	25	Snivasula et al., Mol. Cell 1: 949-957 [1998];									
	26	Hu et al., J. Bio. Chem. 273: 33489-34494 [1998]									
	27		ol. Chem. 273: 1229								
Examiner:											
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM/UC-06646	Serial No.: 10/002,974					
,	RMATIO	N DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)	Applicant: Gabriel Nunez et al.						
(37 CPR \$6.9	&(b))	(Osc Several Sheets II Necessary)	Filing Date: 10/26/01	Group Art Unit:					
70.13 <u>B</u>	2	OTHER DOCUMENTS (Including Author, Title, D	ate, Relevant Pages, Place of Publication)						
	280	McCarthy et al., J. Bio. Chem. 273, 16968-16975 [1998]							
SEP 1 6 2	003 ₂₉ <u>u.</u>	Parniske et al., Cell 91: 821-832 [1997]							
SEP 1 0 Z	36	Dixon et al., Proc. Natl. Acad. Sci. U. S. A. 97: 8807-8814 [2000]							
NEW STAN	RY 31	Aliprantis et al., Science, 285:736-739 [1999]							
	32	Chow et al., J. Biol. Chem., 274/10689-10692 [2000]							
•	33	Bertin et al., J. Biol. Chem., 274:12955-12958 (1999)							
	34	Thome et al., Curr. Biol., 8:885-888 [1998]							
-	35	Inohara et al., J. biol. Chem., 275:27823-27831 [2000]							
	36	Shimada et al., Int. Immunol., 11:1357-1362 [1999]							
	37 Huang et al., PNAS, 94:12829-12832 [1997] 38 Medzhitov et al., Mol. Cell, 2:253-258 [1998] 39 Hsu et al., Immunity, 4:387-396 [1996] 40 Yamaoka et al., Cell 93: 1231-1240 [1998] 41 Hu et al., EMBO J. 18: 3586-3595 [1999]								
	42	42 Karin, J. Biol. Chem. 274: 27339-27342 [1999] 43 Hofmann et al., Trends Biochem. Sci. 22: 155-156 [1997]							
	43								
	44 MacCorkle et al., Proc. Nat. Acad. Sci. U. S. A. 95: 3655-3660 [1998] 45 Yang et al., Nature, 395:284-288 [1998]								
٠									
	46 Zou et al., Cell, 90:405-413 [1997] 47 Poltorak et al., Science, 282:2085 [1998] 48 Takeuchi et al., Immunity, 4:443 [1999] 49 Rietschel et al., Curr Top. Microbiol. Immunol., 216:39-81 [1997] 50 Cho et al., Inflammatory Bowl Diseases 3:186 [1997]								
	51	Cho et al., Proc. Natl. Acad. Sci. 95:7502 [1998]							
1	52 Brant et al., Gastroenterology 115:1056 [1998]								
	53 Cho et al., Hum. Mol. Gent. 9:1425 [2000]								
	54	54 Cavanaugh et al., Ann. Hum. Gent. 62:291 [1998]							
	55 Tysk et al., Gut 29:990 [1988]								
			1						
Examiner: Date Considered:									
EXAMINER:: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									